Patients suffering from dementia with Lewy bodies (DLB) with broad, early stage (Lewy body) LB pathology in the brain, may show mild cardiac sympathetic nerve (CSN) degeneration.
Why this matters
Differentiating between DLB and Alzheimer's disease (AD) is difficult because both LB and AD pathology can coexist in DLB patients.
Reduced cardiac uptake of meta-iodobenzylguanidine (MIBG) is a useful diagnostic biomarker for differentiating DLB from other dementias, including AD.
By understanding residual CSN degeneration in autopsy-confirmed DLB patients, this study may facilitate the accurate diagnosis of DLB in patients suffering from dementia with low MIBG-uptake.